This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, L.
Right arrow Articles by Spellberg, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, L.
Right arrow Articles by Spellberg, B.

 Previous Article

Clinical and Vaccine Immunology, March 2008, p. 582-584, Vol. 15, No. 3
1071-412X/08/$08.00+0     doi:10.1128/CVI.00427-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Considerable Differences in Vaccine Immunogenicities and Efficacies Related to the Diluent Used for Aluminum Hydroxide Adjuvant{triangledown}

Lin Lin,1 Ashraf S. Ibrahim,1,2 Valentina Avanesian,1 John E. Edwards Jr.,1,2 Yue Fu,1,2 Beverlie Baquir,1 Rebecca Taub,1 and Brad Spellberg1,2*

Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California,1 the David Geffen School of Medicine at UCLA, Los Angeles, California2

Received 29 October 2007/ Returned for modification 1 January 2008/ Accepted 4 January 2008

We are developing an anticandidal vaccine using the recombinant N terminus of Als3p (rAls3p-N). We report that although more rAls3p-N was bound by aluminum hydroxide diluted in saline than by aluminum hydroxide diluted in phosphate-buffered saline (PBS), its immunogenicity and efficacy were superior in PBS. Thus, protein binding, by itself, may not predict the efficacy of some vaccines with aluminum adjuvants.

* Corresponding author. Mailing address: Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 W. Carson St., Torrance, CA 90502. Phone: (310) 222-5381. Fax: (310) 782-2016. E-mail: bspellberg{at}labiomed.org

{triangledown} Published ahead of print on 9 January 2008.

Clinical and Vaccine Immunology, March 2008, p. 582-584, Vol. 15, No. 3
1071-412X/08/$08.00+0     doi:10.1128/CVI.00427-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»